{"DataElement":{"publicId":"6576602","version":"1","preferredName":"Gastric Cancer AJCC Edition 8 Postneodjuvant Therapy Group Stage","preferredDefinition":"Postneodjuvant treatment stage group based on the combination of T, N, and M categories and relevant prognostic factors for gastric carcinoma, using AJCC Ed. 8 criteria.","longName":"GAST_AJC8_PTX_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6576380","version":"1","preferredName":"Gastric Neoplasm Post Neoadjuvant Therapy Stage Grouping","preferredDefinition":"Relating to the stomach._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Happening at a time subsequent to a reference time; later in time or order._The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment more effective._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"3443882v1.0:6576378v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3443882","version":"1","preferredName":"Gastric Neoplasm","preferredDefinition":"Relating to the stomach.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C13307:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric","conceptCode":"C13307","definition":"Relating to the stomach.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE9BBA38-E583-4C0E-E040-BB89AD430CAC","latestVersionIndicator":"Yes","beginDate":"2012-04-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-26","modifiedBy":"ONEDATA","dateModified":"2012-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6576378","version":"1","preferredName":"Post Neoadjuvant Therapy Stage Grouping","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.:The administration of therapeutic agents prior to the primary treatment for the purpose of making the primary treatment more effective.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"C38008:C15665:C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C202282-21E9-4053-E053-F662850A099C","latestVersionIndicator":"Yes","beginDate":"2018-12-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-03","modifiedBy":"ONEDATA","dateModified":"2018-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7C202282-21FA-4053-E053-F662850A099C","latestVersionIndicator":"Yes","beginDate":"2018-12-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-03","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"12/3/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6576558","version":"1","preferredName":"Gastric Carcinoma American Joint Committee on Cancer Edition 8 Postneoadjuvant Therapy Group Stage","preferredDefinition":"A term that refers to the postneoadjuvant therapy staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6576558v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IV","valueDescription":"Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8","ValueMeaning":{"publicId":"6576560","version":"1","preferredName":"Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8","longName":"6576560","preferredDefinition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8","conceptCode":"C133673","definition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C3373E5-7259-7558-E053-F662850A605F","latestVersionIndicator":"Yes","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"ONEDATA","dateModified":"2018-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C3373E5-7272-7558-E053-F662850A605F","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"ONEDATA","dateModified":"2018-12-04","deletedIndicator":"No"},{"value":"III","valueDescription":"Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8","ValueMeaning":{"publicId":"6576562","version":"1","preferredName":"Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8","longName":"6576562","preferredDefinition":"Stage III includes: (T4a, N1, M0); (T3, N2, M0); (T2, N3, M0); (T4b, N0, M0); (T4b, N1, M0); (T4a, N2, M0); (T3, N3, M0); (T4b, N2, M0); (T4b, N3, M0); (T4a, N3, M0). T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8","conceptCode":"C133672","definition":"Stage III includes: (T4a, N1, M0); (T3, N2, M0); (T2, N3, M0); (T4b, N0, M0); (T4b, N1, M0); (T4a, N2, M0); (T3, N3, M0); (T4b, N2, M0); (T4b, N3, M0); (T4a, N3, M0). T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C3373E5-727F-7558-E053-F662850A605F","latestVersionIndicator":"Yes","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"ONEDATA","dateModified":"2018-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C3373E5-7298-7558-E053-F662850A605F","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"ONEDATA","dateModified":"2018-12-04","deletedIndicator":"No"},{"value":"II","valueDescription":"Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8","ValueMeaning":{"publicId":"6576564","version":"1","preferredName":"Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8","longName":"6576564","preferredDefinition":"Stage II includes: (T3, N0, M0); (T2, N1, M0); (T1, N2, M0); (T4a, N0, M0); (T3, N1, M0); (T2, N2, M0); (T1, N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8","conceptCode":"C133671","definition":"Stage II includes: (T3, N0, M0); (T2, N1, M0); (T1, N2, M0); (T4a, N0, M0); (T3, N1, M0); (T2, N2, M0); (T1, N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C3373E5-72A5-7558-E053-F662850A605F","latestVersionIndicator":"Yes","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"ONEDATA","dateModified":"2018-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C3373E5-72BE-7558-E053-F662850A605F","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"ONEDATA","dateModified":"2018-12-04","deletedIndicator":"No"},{"value":"I","valueDescription":"Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8","ValueMeaning":{"publicId":"6576566","version":"1","preferredName":"Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8","longName":"6576566","preferredDefinition":"Stage I includes: (T1, N0, M0); (T2, N0, M0); (T1, N1, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8","conceptCode":"C133670","definition":"Stage I includes: (T1, N0, M0); (T2, N0, M0); (T1, N1, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C3373E5-72CB-7558-E053-F662850A605F","latestVersionIndicator":"Yes","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"ONEDATA","dateModified":"2018-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C3373E5-72E4-7558-E053-F662850A605F","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"ONEDATA","dateModified":"2018-12-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6576557","version":"1","preferredName":"Gastric Cancer by AJCC v8 Postneoadjuvant Therapy Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the postneoadjuvant therapy staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C133641:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Cancer by AJCC v8 Postneoadjuvant Therapy Stage","conceptCode":"C133641","definition":"A term that refers to the postneoadjuvant therapy staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C3373E5-722C-7558-E053-F662850A605F","latestVersionIndicator":"Yes","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"ONEDATA","dateModified":"2018-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7C3373E5-723D-7558-E053-F662850A605F","latestVersionIndicator":"Yes","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8/30/19 TMT released per MC.; 12/4/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"10000182","version":"1","longName":"Stomach","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Postneodjuvant therapy diseas","type":"Preferred Question Text","description":"Postneodjuvant therapy disease stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7C33A916-BB26-7DDB-E053-F662850AF47D","latestVersionIndicator":"Yes","beginDate":"2018-12-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-04","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8/30/19 TMT released per MC.; 12/4/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}